Gene Quinn

This week on IPWatchdog Unleashed, I was joined by my longtime friend John White, who is the the creator of the patent bar review course I’ve taught for almost 27 years. Together we explore the intricate and ever changing patent landscape. First, we begin by discussing the bar exam and how it is changing, then we pivot to the evolving role of AI in patent law more generally. Our conversation traversed decades of personal history, friendship and professional insights, revealing how the industry has transformed over the years and what it means for the current and future generation of patent practitioners.

This week on IPWatchdog Unleashed, we feature a panel discussion that took place on October 27 as a part of our annual life sciences program. Initially styled as a conversation about how artificial intelligence is transforming life sciences, it became quickly apparent that the conversation was not going to be limited to the life sciences sector. Instead the discussion evolved into a robust discussion about data risk and intellectual property, focusing on what every innovative company should have front of mind when considering the adoption of AI tools.

In our latest IPWatchdog Unleashed podcast, I spoke with Rob Sahr, shareholder at Wolf Greenfield and co-chair of our 2025 Life Sciences Masters™ program. Our conversation zeroed in on a hard truth the public rarely sees: moving a molecule from early discovery to an FDA-approved therapy requires a chain of scientific and economic miracles—and every one of them leans on a reliable patent system. In this conversation we discuss the extraordinary journey from molecule to medicine. Together, we explore how scientific breakthroughs depend not only on research and capital, but also on a stable and predictable patent system. From double patenting and government funding to judicial uncertainty and policy headwinds, our conversation dives into the fragile balance between innovation and patent policy—and the many scientific miracles required to bring new drugs to life.

One of the ways judges typically evaluate whether a ruling makes sense is to game out the logical consequences of the ruling to see whether it will lead to absurd results. There is little doubt that the U.S. Court of Appeals for the Federal Circuit’s prosecution laches doctrine isn’t just doctrinally off-base—it leads to absurd results, which makes the doctrine structurally unworkable. The Federal Circuit’s presumption that any patent taking more than six years to prosecute is presumptively unenforceable places the burden on patent owners to demonstrate as a threshold matter that the length of prosecution was reasonable. But the brutal, inconvenient truth is that the United States Patent and Trademark Office (USPTO) itself has twice operated secret programs that froze applications for years while telling the outside world nothing.

In our latest IPWatchdog Unleashed podcast, we had a riveting and sometimes emotional conversation that unfolded around one of the most pressing issues in life sciences today: the journey of life-saving drugs from laboratory to patient. We discuss the pivotal role a strong patent system plays in this important journey with guest Sherry Knowles. Sherry is the founder of Knowles Intellectual Property Strategies and former Senior Vice President and Chief Patent Counsel for GlaxoSmithKline. In addition to being one of the leading voices in the life sciences and patent industries, Sherry is also a cancer survivor. Among other things we discuss numerous patent system challenges facing innovator drug companies, the downward pressure generic drugs place on the industry and leading to important drugs becoming unavailable, the role of Pharmacy Benefit Managers (PBMs) with respect to significantly raising the cost of drugs for Americans, and policy influences and legislation on Capitol Hill. Sherry also shares her personal story and insights into why patents are more than just legal constructs—they are deeply personal lifelines.